Lv1
20 积分 2024-01-25 加入
Long-Term Follow-up of Low-Dose Dasatinib (50mg Daily) As Frontline Therapy in Newly Diagnosed Chronic Myeloid Leukemia
1年前
已关闭
Clinical management of second-generation tyrosine kinase inhibitor therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase, focusing on age and dose effects
1年前
已关闭
Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up Results
1年前
已关闭
Attenuated Dose Dasatinib in Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase Patients in India
1年前
已完结
Dasatinib dosing strategies in Philadelphia chromosome-positive leukemia
1年前
已完结
Dasatinib
1年前
已完结
皖公网安备34019202002308
